These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 17078482)

  • 1. Antiretroviral therapy in AIDS patients with tuberculosis.
    Moreno S; Hernández B; Dronda F
    AIDS Rev; 2006; 8(3):115-24. PubMed ID: 17078482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2000 Mar; 49(9):185-9. PubMed ID: 11795500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Boosted protease inhibitor-based or nonnucleoside reverse transcriptase-based HAART: is there a best choice for antiretroviral-naive HIV-1 infected patients?
    Cuzin L; Allavena C; Morlat P; Dellamonica P
    AIDS Rev; 2008; 10(4):205-11. PubMed ID: 19092976
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TB drugs interact adversely with protease inhibitors.
    AIDS Alert; 1996 Oct; 11(10):117-8. PubMed ID: 11363854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Issues in the treatment of active tuberculosis in human immunodeficiency virus-infected patients.
    Schluger NW
    Clin Infect Dis; 1999 Jan; 28(1):130-5. PubMed ID: 10028083
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries.
    Maartens G; Decloedt E; Cohen K
    Antivir Ther; 2009; 14(8):1039-43. PubMed ID: 20032533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acquired rifamycin resistance in persons with advanced HIV disease being treated for active tuberculosis with intermittent rifamycin-based regimens.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2002 Mar; 51(10):214-5. PubMed ID: 11922192
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complications of antiretroviral therapy in patients with tuberculosis: drug interactions, toxicity, and immune reconstitution inflammatory syndrome.
    McIlleron H; Meintjes G; Burman WJ; Maartens G
    J Infect Dis; 2007 Aug; 196 Suppl 1():S63-75. PubMed ID: 17624828
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug-drug interactions in inmates treated for human immunodeficiency virus and Mycobacterium tuberculosis infection or disease: an institutional tuberculosis outbreak.
    Spradling P; Drociuk D; McLaughlin S; Lee LM; Peloquin CA; Gallicano K; Pozsik C; Onorato I; Castro KG; Ridzon R
    Clin Infect Dis; 2002 Nov; 35(9):1106-12. PubMed ID: 12384845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Warfarin-antiretroviral interactions.
    Liedtke MD; Rathbun RC
    Ann Pharmacother; 2009 Feb; 43(2):322-8. PubMed ID: 19196837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rifamycin-resistant Mycobacterium tuberculosis in the highly active antiretroviral therapy era: a report of 3 relapses with acquired rifampin resistance following alternate-day rifabutin and boosted protease inhibitor therapy.
    Jenny-Avital ER; Joseph K
    Clin Infect Dis; 2009 May; 48(10):1471-4. PubMed ID: 19368504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Possible antiretroviral therapy-warfarin drug interaction.
    Fulco PP; Zingone MM; Higginson RT
    Pharmacotherapy; 2008 Jul; 28(7):945-9. PubMed ID: 18576910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nevirapine levels after discontinuation of rifampicin therapy and 60-week efficacy of nevirapine-based antiretroviral therapy in HIV-infected patients with tuberculosis.
    Manosuthi W; Ruxrungtham K; Likanonsakul S; Prasithsirikul W; Inthong Y; Phoorisri T; Sungkanuparph S
    Clin Infect Dis; 2007 Jan; 44(1):141-4. PubMed ID: 17143831
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis.
    Burman WJ; Gallicano K; Peloquin C
    Clin Infect Dis; 1999 Mar; 28(3):419-29; quiz 430. PubMed ID: 10194057
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro.
    Jevtović DO; Salemović D; Ranin J; Pesić I; Zerjav S; Djurković-Djaković O
    HIV Med; 2007 Mar; 8(2):75-9. PubMed ID: 17352762
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical evaluation of the nelfinavir-rifabutin interaction in patients with tuberculosis and human immunodeficiency virus infection.
    Benator DA; Weiner MH; Burman WJ; Vernon AA; Zhao ZA; Khan AE; Jones BE; Sandman L; Engle M; Silva-Trigo C; Hsyu PH; Becker MI; Peloquin CA;
    Pharmacotherapy; 2007 Jun; 27(6):793-800. PubMed ID: 17542762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liver injury in HIV-1-infected patients receiving non-nucleosides reverse transcriptase inhibitors-based antiretroviral therapy.
    Li ZC; Li HJ; Dai LL; Gao YQ; Cai WP; Li HY; Huang XJ; Zhang T; Wu H
    Chin Med J (Engl); 2010 Dec; 123(24):3587-90. PubMed ID: 22166636
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of PI and NNRTI HAART-based therapy on oral lesions of Brazilian HIV-infected patients.
    Ortega KL; Vale DA; Magalhães MH
    J Oral Pathol Med; 2009 Jul; 38(6):489-94. PubMed ID: 19453845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberculosis and HIV co-infection: a practical therapeutic approach.
    Breen RA; Swaden L; Ballinger J; Lipman MC
    Drugs; 2006; 66(18):2299-308. PubMed ID: 17181373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.